Low-dose aspirin and prostate cancer-specific mortality

A newly published article — and an associated editorial — in the Annals of Internal Medicine has addressed the possible benefits of taking low-dose aspirin as a method to prevent the progression of newly diagnosed prostate cancer. … READ MORE …

Diet, diagnosis, AS, and the management of lower-risk forms of prostate cancer

Over the years there has been a great deal of speculation (and a very small amount of data) suggesting that men who get diagnosed with relatively low-risk forms of prostate cancer may be able to delay progression of their disease by eating the right diet. … READ MORE …

But can exercise lower risk for prostate cancer diagnosis or progression?

In an incidentally timely manner, the May issue of Annals of Oncology carries a systematic review and meta-analysis of data on physical activity and risk for prostate cancer. … READ MORE …

The MEAL study — an update

Back in 2011, what is now the Alliance for Clinical Trials in Oncology (ACTO) but was then CALGB (Cancer and Leukemia Group B) initiated the Men’s Eating and Living (MEAL) study. This trial is, we hope, going to give us some real answers to a very important question: does diet affect risk for the progression of prostate cancer in men on active surveillance? … READ MORE …

Should every prostate cancer patient be on a statin?

A recent article in the Journal of Clinical Oncology, together with an associated editorial, have addressed the issue of whether evidence is now sufficient to argue that all men with prostate cancer should be treated with a statin. … READ MORE …

Age, active surveillance, and age-related risk for progression

A new report in the Journal of Clinical Oncology suggests that younger patients had a somewhat lower risk for biopsy-based Gleason score upgrade while on active surveillance (AS) than older patients. … READ MORE …

Numbers progressing and time to progression on active surveillance

A new study just published in the World Journal of Urology has provided us with data from the Prostate Cancer Outcomes Registry — Victoria (in Australia) on the progression of men initially managed on active surveillance. … READ MORE …

ADT + sipuleucel-T in treatment of hormone-sensitive prostate cancer

One of the major unanswered questions at this time is whether immunotherapy of some type, if given early to patients with prostate cancer, can help to lower risk of progression of the disease. … READ MORE …

A better way to identify risk for metastasis?

According to a news report on the ScienceDaily web site, researchers in the UK have identified a subgroup of circulating tumor cells (CTCs) in patient’s blood that seem to be linked to risk for progression and spread of prostate cancer. … READ MORE …

Statins in the prevention and management of prostate cancer: an update

A recent review article in the journal Nature Reviews: Urology has concluded that, while we are learning a lot more about the potential role(s) of statins in the prevention and management of prostate cancer, we still have no definitive evidence of their value. … READ MORE …

PORTOS: a gene signature that predicts salvage radiation success

Salvage radiation is curative in roughly half of all cases. There are many factors that contribute to an unfavorable prognosis, including waiting too long, high PSA and rapid PSA doubling time, adverse post-surgery pathology (stage, Gleason score, positive margins), and high Decipher or CAPRA-S scores. But, … READ MORE …

Non-rising PSA but radiographic progression in men on treatment with enzalutamide

A recent presentation at the European Society of Medical Oncology (ESMO) annual meeting in Copenhagen, Denmark, has suggested that some men on treatment with enzalutamide (Xtandi) may have radiographic progression of their cancer even though there is no increase in their PSA levels. … READ MORE …

Is IL-33 expression a key to risk for prostate cancer progression and metastasis?

According to a newly published article in the journal Scientific Reports, men who lose normal expression of a protein known as interleukin-33 or IL-33 are at higher risk for recurrence of their prostate cancer within 5 years than men who do not lose the expression of this biomarker. … READ MORE …

Life, behavior, and prostate cancer risk: should you be shedding a few pounds?

The capacity of the average male human to do things that are probably not very good for his health (and to not do things that probably would be good for his health) is considerable. At the most basic level, for example, most of us here in the US don’t eat very wisely and don’t take anything like enough exercise. … READ MORE …

What to do with a man with M0 or M1 disease who is progressing on treatment

Is the addition of enzalutamide (Xtandi) to an LHRH agonist now the appropriate standard of care for a man with M0 or M1 prostate cancer who starts to progress on treatment with an LHRH agonist alone? … READ MORE …